13:00
May 11

Cannabotech raised NIS 1.2 million in a public offering

11:30
May 10

Together achieved an export permission from Germany to UK

14:00
January 20

Panaxia reports the first export of cannabis tablets to France as part of the pilot in which it participates and is expected to last about two years. The tablets were delivered to France free of charge.

13:00
January 22

Togther reports that the Securities Authority has initiated administrative enforcement proceedings against it in respect of its previous reports from 2018 and 2019 regarding business relations with China.

Recent News

May 17, 2022

Revenue growth is expected to continue in the second quarter and throughout 2022 due to organic growth, acquisition of ‘Better’, and international expansion…

April 25, 2022

Cronos and Intercure have similar EV and revenue, but the profitability is very different …

April 7, 2022

The medical cannabis market in Israel is one of the fastest growing in the world. According to data published by the Israeli Medical Cannabis…

March 22, 2022

InterCure (NASDAQ: INCR) and Clever Leaves (NASDAQ: CLVR) today announced the execution of an exclusive multi-year cultivation, marketing and distribution agreement. Over the term…

Israeli cannabis companies have paid over NIS 100 million (USD 31 million) to purchase pharmacies in the last six months

Almost all public cannabis companies in Israel have purchased pharmacies lately. This will increase their revenues and market cap

givol pharmacy
Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on telegram
Share on email

The pharmacy industry in Israel is on fire. In the last six months, Israeli cannabis companies have cumulatively reported at least nine transactions for the purchase of pharmacies.

However, it seems that the prices paid for pharmacies vary a very wide range of between one million NIS and twenty-five million NIS.

First, we will understand why Israeli cannabis companies so eager to buy a pharmacy. Their stated purpose, as mentioned in almost every transaction report is to complete the value chain and to become vertically integrated. A pharmacy enables a manufacturer of medical cannabis to be in direct contact with patients, receive feedback from them, and thus continue to develop products that suit the changing needs of patients.

A pharmacy has another benefit in that it prioritizes the sales of the “home” brands.

So far everything is known.

Our analysis shows that transactions are made at a price-to-sales (P/S) ration raging between 0.6 to 1.1. Meaning that, on average, cannabis companies pay for a pharmacy less than its annual revenue. In contrast, cannabis companies in Israel are traded on the stock exchange at P/S ratio raging between 1 to 4.4. As a result, increasing revenue by purchasing a pharmacy is expected to increase the value of the cannabis company at a significantly higher rate than what they paid.

For example, Intercure (ticker: INCR) acquired MaxPharm pharmacy chain last September, which operates pharmacies in Holon and Rishon Lezion. Intercure acquired 55% of the chain in the transaction. As is well known, in the holding of over 50.1% the financial statements of the acquiring company are consolidated into the financial results of the acquiring company. In other words, revenues from MaxPharm will appear in Intercure’s financial results starting from the middle of the third quarter.

Intercure paid a total of NIS 16.7 million for 55% of the shares, some in cash and some in shares and options. The value of MaxPharm in the transaction is NIS 25 million. The chain’s revenues in the first half of 2021 were NIS 16 million. That is, a P/S ratio of 0.8.

Intercure is currently traded at a value of NIS 961m, and with annual revenues in 2021 standing at NIS 217m, the company’s P/S ratio is 4.4. Assuming that the income from MaxPharm will be priced by the market in the same way as the rest of the company, the increase in the pharmacy’s income amounting NIS 32 million per year may be reflected in an increase in the value of intercure of NIS 140 million (some are attributed to non-controlling interests).

For that reason, this is a great acquisition for Intercure. In addition, this added value might be even higher, since the pharmacy has growth potential after being acquired by a cannabis company.

Other main transactions in the last six months:

Last July, IMC (NYSE: IMCC) acquired the Green Pharm Group, for NIS 11.9 million. Green Pharm includes two pharmacies: Green Pharm in Netanya, Hi Way and another company with a transportation license. IMC has also acquired the panaxia-to-the-Home online pharmacy and trading center.

At the same time, Univo acquired the Medipharm pharmacy located in Holon. Univo purchased 51% of the pharmacy, at a value of NIS 14 million.

Seach Medical purchased two pharmacies: Tifrachat in northern Israel at a value of NIS 16 million and a Even-Chen in Sharon area at a value of NIS 6 million. The company also announced another purchase of a pharmacy in Tel Aviv.

Cannassure bought a pharmacy in Tel Aviv and paid NIS 1 million. This is the cheapest deal recently announced.

Amir Marketing announced that BOL Pharma has signed an agreement to purchase the online pharmacy Telpharma at a value of 21 million.

Details of the sales volumes were given in only four of these transactions, so the table lists only those for which a P/S ration can be calculated:

P/S ratio % purched Valuation Location Deal date Pharmacy Name Company
1.1 0.501 16 Kiryat Yam Oct-21 Tifrachat Seach Medical
0.9 0.51 14 Holon Jun-21 MediPharm Univo Pharma
0.8 0.55 25 Holon+Rishon Sep-21 MaxPharm Intercure
0.6 1 11.9 Netania Jul-21 Pharm Yarok IMC

 

Why are there such big differences between the prices of the different pharmacies? Apparently there are a number of parameters that determine the price of the pharmacy:

  1. Revenue and profitability.
  2. The growth potential of the pharmacy – Given the number of medical cannabis patients in the geographical area and the deployment of competing pharmacies.
  3. Deliveries – Does the pharmacy make deliveries and to what geographical distance.
  4. The nature of the developers of the pharmacy.

 

As far as pharmacy owners are concerned, they also have an interest in being purchased by a cannabis company. The ownership of a cannabis company gives the pharmacy priority, even if not official, for the more high-demand products and limited stock of coveted batches. In addition, for the pharmacy owner, this is sometimes a nice exit for a family business, which without the medical cannabis couldn’t be sold.

For cannabis companies, beyond the increase in revenue and other benefits mentioned, there is also long-term aspect. When Israel will have recreational legalization, many pharmacies are infrastructure for future dispensaries chains.

Share your thoughts, add a comment

Your email address will not be published.